Uncategorized
STAT+: A new ranking of pharma companies by R&D performance
Good morning. I’m feeling jealous of my colleagues who get to enjoy some good weather today in San Francisco for our Breakthrough West Summit.
The need-to-know this morning
- Relay Therapeutics reported promising Phase 2 data of its drug zovegalisib in a group of rare diseases that cause abnormal vasculature development, sending company shares up 9% in premarket trading.
Lilly tops peers on R&D performance, report finds
Eli Lilly ranked first in not one, but two categories in a prominent analysis of drugmakers’ R&D activity.
Every year, the consulting firm IDEA Pharma ranks companies on innovation, which takes into account revenue from new drugs; and invention, which looks at the number of drugs a company has in development and its R&D investment. This is the first time that one company has ranked first in both categories.
Good morning. I’m feeling jealous of my colleagues who get to enjoy some good weather today in San Francisco for our Breakthrough West Summit.
The need-to-know this morning
- Relay Therapeutics reported promising Phase 2 data of its drug zovegalisib in a group of rare diseases that cause abnormal vasculature development, sending company shares up 9% in premarket trading.
Lilly tops peers on R&D performance, report finds
Eli Lilly ranked first in not one, but two categories in a prominent analysis of drugmakers’ R&D activity.
Every year, the consulting firm IDEA Pharma ranks companies on innovation, which takes into account revenue from new drugs; and invention, which looks at the number of drugs a company has in development and its R&D investment. This is the first time that one company has ranked first in both categories.